


COG133

01/20

ALTERNATE NAME: apoE(133-149)

CATALOG #: B2969-1 1 mg
B2969-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{97}H_{181}N_{37}O_{19}$

MOLECULAR WEIGHT: 2169.73

CAS NUMBER: 514200-66-9

APPEARANCE: Solid

PEPTIDE SEQUENCE Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-NH₂

PURITY: 99%

SOLUBILITY: ~1 mg/ml in Water
~217 mg/ml in DMSO

DESCRIPTION: COG 133 is a fragment of Apolipoprotein E (APOE) that mimics the anti-inflammatory and neuroprotective effects of the intact apoE protein. It functions through the low-density lipoprotein receptor-related protein (LRP). It reduces the symptoms of experimental autoimmune encephalomyelitis model of human multiple sclerosis, suppresses inflammation, demyelination and infiltration of cells into the spinal cord. It also acts as a non-competitive antagonist at $\alpha 7$ nicotinic acetylcholine receptors with an IC₅₀ of 445 nM.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Gay, E.A., Klein, R.C., Yakel, J.L. Apolipoprotein E-derived peptides block $\alpha 7$ neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. *J Pharmacol Exp Ther.* 316(2):835-42 (2006).
2. Li, F.Q., Sempowski, G.D., McKenna, S.E. et al. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. *J Pharmacol Exp Ther.* 318(3):956-65 (2006).
3. Sheng, Z., Prorok, M., Brown, B.E. et al. N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. *Neuropharmacology.* 55(2):204-14 (2008).

RELATED PRODUCTS:

EZSolution™ Triacsin C (Cat. No. 9683)
 Atorvastatin (Cat. No. 2278)
 Simvastatin (Cat. No. 1693)
 ProbucoI (Cat. No. B2968)
 Lovastatin (Cat. No. 1692)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*